ライフサイエンスコーパス: non-melanoma skin cancer

1 CI 0.57-0.91, p=0.0042), owing primarily to non-melanoma skin cancer.

2 HPV8 and 77) are suspected to be involved in non-melanoma skin cancer.

3 ll-recognized etiologic factor for cutaneous non-melanoma skin cancer.

4 ynamic therapy (PDT) is widely used to treat non-melanoma skin cancer.

5 tis, viral warts, molluscum contagiosum, and non-melanoma skin cancer.

6 asal alar lobule after two-layer excision of non-melanoma skin cancer.

7 story of photosensitizing medication use and non-melanoma skin cancer.

8 as for the identification of target cells in non-melanoma skin cancer.

9 facing to reduce or prevent aging-associated non-melanoma skin cancer.

10 are novel loci conferring susceptibility to non-melanoma skin cancer.

11 ated by UV irradiation, the primary cause of non-melanoma skin cancer.

12 omponent in the development of aging-related non-melanoma skin cancer.

13 e development and progression of UVB-induced non-melanoma skin cancer.

14 tologists treat actinic keratoses to prevent non-melanoma skin cancer.

15 s a significant factor in the development of non-melanoma skin cancer.

16 dministration of ARD on at least one type of non-melanoma skin cancer.

17 arge, population-based case-control study of non-melanoma skin cancer.

18 A confers an increased risk for melanoma and non-melanoma skin cancer.

19 mental factors contribute to pathogenesis of non-melanoma skin cancers.

20 tive and site-specific approach for managing non-melanoma skin cancers.

21 disorders (18.2%), prostate cancers (18.2%), non-melanoma skin cancers (18.2%), and breast cancers (1

22 43; and with skin cancer (Bowen's disease or non-melanoma skin cancer), 378.

23 was for prostate cancer (77.0% in April) and non-melanoma skin cancer (72.4% in April).

24 oming available, especially for treatment of non-melanoma skin cancer and Barrett's oesophagus, and i

25 cell carcinoma (SCC) is the most aggressive non-melanoma skin cancer and is dramatically increased i

26 is associated with solid cancers, including non-melanoma skin cancer and lung cancer, and that CHIP

27 dent cancer cases were documented (excluding non-melanoma skin cancer and non-aggressive prostate can

28 r transmission from donors with a history of non-melanoma skin cancer and selected cancers of the CNS

29 ln399gln) is associated with a lower risk of non-melanoma skin cancer and suggest that the etiology o

30 have a prevalent cancer at baseline (except non-melanoma skin cancer) and had provided data on oral

31 antified for all cancers combined, excluding non-melanoma skin cancer, and 33 specific cancer types.

32 nts as evidenced by the fact that 80% of all non-melanoma skin cancers are diagnosed in patients over

33 treatment of pre-cancerous skin lesions and non-melanoma skin cancers are not completely effective.

34 issue and ease of observation, acceptance of non-melanoma skin cancers as model carcinomas has been h

35 TP53 is an accepted UVR target in human non-melanoma skin cancer, but is not thought to have a m

36 for the majority of the approximately 10,000 non-melanoma skin cancer deaths in the United States ann

37 s, leading to more than one million cases of non-melanoma skin cancer diagnosed annually in the Unite

38 ity for all incident cancer cases, excluding non-melanoma skin cancers, diagnosed between 2002 and 20

39 's lymphoma (SIR=28.56, 95% CI, 7.68-73.11), non-melanoma skin cancer (estimated SIR> or =3.16) and f

40 We have demonstrated that non-melanoma skin cancers express functional purinergic

41 Photodynamic therapy (PDT) to manage non-melanoma skin cancers has garnered great attention o

42 The rising incidence and morbidity of non-melanoma skin cancers has generated great interest i

43 an early warning sign of progression toward non-melanoma skin cancer, if ignored.

44 tions in p53 were detected in 11/23 (48%) of non melanoma skin cancers in renal allograft recipients

45 en shown to contribute to the development of non-melanoma skin cancer in humans.

46 om an incident survey of all newly diagnosed non-melanoma skin cancer in New Hampshire, and controls

47 een implicated in the increased incidence of non-melanoma skin cancer in transplant recipients, most

48 Another group of HPVs causes non-melanoma skin cancers in genetically predisposed or

49 trum of HPV types are also commonly found in non-melanoma skin cancers in immunocompromised individua

50 6 women were diagnosed with cancer excluding non-melanoma skin cancer, in Denmark.

51 Non-melanoma skin cancer is a disease primarily afflicti

52 The development of extensive and severe non-melanoma skin cancer is an extremely common complica

53 Diagnosis of non-melanoma skin cancer is made clinically and confirme

54 mulation of genetic change and behaviour for non-melanoma skin cancer is not straightforward.

55 This approach is limited because non-melanoma skin cancer is predominantly formed on body

56 Non-melanoma skin cancer is the most common cancer world

57 Currently, the only effective treatment for non-melanoma skin cancer is the removal of the tumors af

58 The incidence of keratinocyte-derived (non-melanoma) skin cancers is increasing rapidly.

59 al thrombosis, thrombophilia, cancer (except non-melanoma skin cancer), liver disease, chronic kidney

60 For example, unlike non-melanoma skin cancers, melanoma is not restricted to

61 iagnosed with cancer before 1986 (other than non-melanoma skin cancer, n=2076) and those with missing

62 nsplant recipients have an increased risk of non-melanoma skin cancer (NMSC) compared to in the gener

63 This approach is limited because non-melanoma skin cancer (NMSC) is predominantly formed

64 Non-melanoma skin cancer (NMSC) is the most common cance

65 Non-melanoma skin cancer (NMSC) is the most common malig

66 Non-melanoma skin cancer (NMSC) represents a significant

67 sue injury, represents a clinical marker for non-melanoma skin cancer (NMSC) risk.

68 genes was related to EMAST in a series of 61 non-melanoma skin cancer (NMSC) tumors.

69 Given the high incidence of non-melanoma skin cancer (NMSC), a preventative interven

70 sociation between UVB and the development of non-melanoma skin cancer (NMSC), controlling for known c

71 type are risk factors for the development of non-melanoma skin cancer (NMSC), including basal cell ca

72 buting factor in ultraviolet B (UVB)-induced non-melanoma skin cancer (NMSC), which consists primaril

73 neous beta-HPV infection and a high risk for non-melanoma skin cancer (NMSC).

74 genes are associated with susceptibility to non-melanoma skin cancer (NMSC).

75 iseases is associated with decreased risk of non-melanoma skin cancer (NMSC).

76 r of sunburns, tanning ability and number of non-melanoma skin cancers (NMSCs) among 10 183 European

77 Non-melanoma skin cancers (NMSCs) are among the most com

78 Non-melanoma skin cancers (NMSCs) are the most common ma

79 e of overall de novo malignancies (excluding non-melanoma skin cancers [NMSCs]), post-transplantation

80 73 malignancies other than non-melanoma skin cancer occurred (SIR 0.9 [95% CI 0.7-1

81 =50% size of alar subunit) after excision of non-melanoma skin cancer on the alar lobule.

82 serious infections, herpes zoster infection, non-melanoma skin cancer, other malignancies, major card

83 Non-melanoma skin cancer represents the most common canc

84 HPV DNA was detected in 15 of 20 (75%) non-melanoma skin cancer, seven of 17 (41.2%) dysplastic

85 Non-melanoma skin cancer, the most common neoplasia afte

86 rincipal aetiological factor associated with non-melanoma skin cancer, the most prevalent group of ma

87 In 2023, excluding non-melanoma skin cancers, there were 18.5 million (95%

88 mouse model of UVB-induced inflammation and non-melanoma skin cancer to further define sex discrepan

89 st examples of video-mosaics of melanoma and non-melanoma skin cancers, to demonstrate potential clin

90 suggested an association between eczema and non-melanoma skin cancer, while the remaining study fail